Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus

Objective:  The aim of this study was to compare safety, metabolic control, and treatment satisfaction in children/adolescents at onset of type 1 diabetes mellitus who were treated with either continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

[1]  L. Gortner,et al.  Shorter remission period in young versus older children with diabetes mellitus type 1. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  A. Finkelstein,et al.  Insulin pump therapy from the time of diagnosis of type 1 diabetes. , 2006, Diabetes technology & therapeutics.

[3]  R. Hanås,et al.  Insulin pumps in pediatric routine care improve long‐term metabolic control without increasing the risk of hypoglycemia , 2006, Pediatric diabetes.

[4]  P A McKinney,et al.  Insulin pump therapy in childhood diabetes—cost implications for Primary Care Trusts , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[5]  M. Rewers,et al.  Use of insulin glargine in children under age 6 with type 1 diabetes , 2005, Pediatric diabetes.

[6]  T. Jones,et al.  Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[7]  W. Tamborlane,et al.  A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. , 2004, Diabetes care.

[8]  Cas Weykamp,et al.  IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. , 2004, Clinical chemistry.

[9]  Moshe Phillip,et al.  Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. , 2003, Pediatrics.

[10]  P. Scuffham,et al.  The cost‐effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[11]  T. Erlinger,et al.  Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. , 2003, Diabetes care.

[12]  G. Ghirlanda,et al.  A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). , 2003, Diabetes technology & therapeutics.

[13]  M. Freemark,et al.  Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. , 2002, The Journal of pediatrics.

[14]  J. Speight,et al.  Patient perceptions of diabetes and diabetes therapy: assessing quality of life , 2002, Diabetes/metabolism research and reviews.

[15]  John Pickup,et al.  Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials , 2002, BMJ : British Medical Journal.

[16]  W. Tamborlane,et al.  Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups , 2002, Pediatric diabetes.

[17]  J. van Dyk,et al.  Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents with Type I Diabetes Mellitus , 2002, Journal of pediatric endocrinology & metabolism : JPEM.

[18]  C. Bradley,et al.  Treatment satisfaction and psychological well‐being with insulin glargine compared with NPH in patients with Type 1 diabetes , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[19]  H. Chase,et al.  Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. , 2001, Pediatrics.

[20]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[21]  M. Wake,et al.  The Child Health Questionnaire in children with diabetes: cross‐sectional survey of parent and adolescent‐reported functional health status , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[22]  I. Hirsch,et al.  Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. , 2000, Diabetes care.

[23]  W. Tamborlane,et al.  Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. , 1999, Diabetes care.

[24]  T. Cole,et al.  Swedish population reference standards for height, weight and body mass index attained at 6 to 16 years (girls) or 19 years (boys) , 1995, Acta paediatrica.

[25]  Diabetes Control.  Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. , 1994, The Journal of pediatrics.

[26]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[27]  C. Bradley,et al.  Guidelines for Encouraging Psychological Well‐being , 1994 .

[28]  C. Bradley,et al.  Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[29]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[30]  C. de Beaufort,et al.  Psychological impact of continuous subcutaneous insulin infusion pump therapy in non-selected newly diagnosed insulin dependent (type 1) diabetic children: evaluation after two years of therapy. , 1990, Diabete & metabolisme.

[31]  C. Bradley,et al.  Measures of Psychological Well‐being and Treatment Satisfaction Developed from the Responses of People with Tablet‐treated Diabetes , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[32]  G. Bruining,et al.  Continuous Subcutaneous Insulin Infusion (CSII) Versus Conventional Injection Therapy in Newly Diagnosed Diabetic Children: Two‐year Follow‐up of a Randomized, Prospective Trial , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[33]  L. Regeur,et al.  Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. , 1979, British medical journal.

[34]  W. Tamborlane,et al.  Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. , 1979, The New England journal of medicine.

[35]  H Keen,et al.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. , 1978, British medical journal.